Search bioRxivSearch

Biology subjects

Daniel Durocher

Publications and source records attributed to Daniel Durocher.

2 recordsLinked to original sources

A Pif1-dependent threshold separates DNA double-strand breaks and telomeres

The natural ends of chromosomes resemble DNA double-strand breaks (DSBs) and telomeres are therefore necessary to prevent recognition by the DNA damage response. The enzyme telomerase can also generate new telomeres at DSBs, resulting in the loss of genetic information distal to the break. How cells deal with different DNA ends is therefore an important decision. One critical point of regulation is to limit telomerase activity at DSBs and this is primarily accomplished in budding yeast by the telomerase inhibitor Pif1. Here we use Pif1 as a sensor to gain insight into the cellular decision at DSB ends with increasing telomeric character. We uncover a striking transition point in which 34 bp of telomeric (TG1-3)n repeat sequence is sufficient to render a DNA end insensitive to Pif1, thereby facilitating extension by telomerase. This phenomenon is unlikely to be due to Pif1 modification and we propose that Cdc13 confers a unique property to the TG34 end that prevents Pif1 action. We identify novel Cdc13 mutations that resensitize DNA ends to Pif1 and discover that many Cdc13 telomerase-null mutations are dependent on Pif1 status. Finally, the observed threshold of Pif1 activity recapitulates several properties of both DSBs and telomeres and we propose that this is the dividing line between these entities.

Molecular Biology

A genetically encoded inhibitor of 53BP1 to stimulate homology-based gene editing

The expanding repertoire of programmable nucleases such as Cas9 brings new opportunities in genetic medicine1-3. In many cases, these nucleases are engineered to induce a DNA double-strand break (DSB) to stimulate precise genome editing by homologous recombination (HR). However, HR efficiency is nearly always hindered by competing DSB repair pathways such as non-homologous end-joining (NHEJ). HR is also profoundly suppressed in non-replicating cells, thus precluding the use of homology-based genome engineering in a wide variety4 of cell types. Here, we report the development of a genetically encoded inhibitor of 53BP1 (known as TP53BP1), a regulator of DSB repair pathway choice5. 53BP1 promotes NHEJ over HR by suppressing end resection, the formation of 3-prime single-stranded DNA tails, which is the rate-limiting step in HR initiation. 53BP1 also blocks the recruitment of the HR factor BRCA1 to DSB sites in G1 cells4,6. The inhibitor of 53BP1 (or i53) was identified through the screening of a massive combinatorial library of engineered ubiquitin variants by phage display7. i53 binds and occludes the ligand binding site of the 53BP1 Tudor domain with high affinity and selectivity, blocking its ability to accumulate at sites of DNA damage. i53 is a potent selective inhibitor of 53BP1 and enhances gene targeting and chromosomal gene conversion, two HR-dependent reactions. Finally, i53 can also activate HR in G1 cells when combined with the activation of end-resection and KEAP1 inhibition. We conclude that 53BP1 inhibition is a robust tool to enhance precise genome editing by canonical HR pathways.

Molecular Biology